The News Releases listed
below describe just a few of the exciting
things happening at MPI Research. Click on
each one to read the full story.
- MPI Research Expansion in Kalamazoo
MPI Research is pleased to announce its intent to take over two laboratory buildings in downtown Kalamazoo. Pfizer vacated the buildings, and MPI Research will renovate them to accommodate its growing discovery services. Read more details at MPI Research Expands into Kalamazoo Pfizer Buildings.
- Medicilon/MPI Preclinical Research Shanghai Introduces Board of Directors
Mattawan, MI
(April 2008) - Medicilon/MPI Preclinical Research Shanghai has announced its newly formed Board of Directors, which has equal representation from the two parent companies. The four
directors include executives William U. Parfet and William Harrison from MPI Research, and Drs. Chun-Lin Chen and Jintao Zhang from Medicilon.
- MPI Research Announces
Key Positions
Mattawan, MI
(February 2008) - MPI Research recently
announced two key appointments. Zheng
Jim Wang, PhD, is the Director of Molecular
Imaging and Stefano F. Liparoto, PhD,
is the Director of Immunology, and will
head the company’s Immunoassay
and Immunotoxicology area. As experts
in their fields, the addition of Dr.
Wang and Dr. Liparoto will expand the
capabilities of MPI Research in these
areas that are increasingly important
to the drug discovery development programs
of its Sponsors.
- MPI Research
and Shanghai Medicilon Announce Shanghai-Based
Joint Venture
MPI Research and Shanghai Medicilon are pleased to announce a new joint venture to form Medicilon-MPI
Preclinical Research (Shanghai) LLC. Located initially at the Zhangjiang Hi-Tech Park in Shanghai, China,
the company will open a 50,000ft2 preclinical testing facility in the Chuansha Economic Park in early 2008.
This new facility will meet the regulatory standards set forth by the US FDA and other regulatory agencies
worldwide.
- MPI Research
at AusBiotech 2007 National Conference
October 21-24 in Brisbane
MPI Research, a global provider of preclinical
drug discovery and development services
for the pharmaceutical and biotechnology
industries, will have an active role
at the AusBiotech 2007 National Conference
being held at the Brisbane Convention
and Exhibition Center in Brisbane, Queensland,
Australia from October 21 through October
24. The company will present a half-day
educational seminar, Aiming for Preclinical
Success, on October 21 from 1:30 pm to
5:30 pm on the mezzanine level of the
convention center.
- MPI Research Fills Key Leadership Positions
Two high
level appointments within MPI Research
were recently announced. David
Serota, PhD, DABT, was promoted
to the position of Vice President, Toxicology and Pathology and will also serve
as a member of the company’s senior
management team. Tina Rogers, PhD, DABT, joined the company as the Associate
Director of Research. Both appointments further strengthen the leadership position
MPI Research has earned within the Contract Research Organization (CRO) industry.
- MPI
Research Continues Toxicology Expansion
Additional capacity keeps the pharmaceutical
industry's preclinical drug development
programs moving forward - As part of a series of planned expansions, MPI Research announced the immediate availability of additional toxicology capacity today. Through its portfolio of services the company generates critical safety data for the pharmaceutical and biotechnology industries prior to a new drug candidate's introduction to humans.
- MPI
Research Presents Annual Education
Summit - Advances in Therapeutic
Discovery & Drug Development:
Preclinical Cell-Based Therapy Research
- MPI
Research, a preclinical contract
research organization that sponsors
annual educational summits, is proud
to present, Advances in Therapeutic
Discovery and Drug Development: Preclinical
Cell-Based Therapy Research, August
15-17, 2007 at the historic and picturesque
Brook Lodge in Augusta, Michigan.
- MPI
Research at Japanese Society of Toxicology
June 27-29 in Tokyo - As
a global leader in preclinical research
for the pharmaceutical and biotech
industries, MPI Research will be
active at the esteemed Japanese Society
of Toxicology (JST) meeting being
held at the Tower Hall Funabori in
Tokyo, Japan on June 27-29, 2007.
- MPI Research Teams with NYBA
MPI Research presents and exhibits
at the 16th Annual Meeting of the
New York Biotechnology Association
(NYBA) on April 10, 2007 - MPI
Research is pleased to be an integral
part of the 16th NYBA annual meeting,
being held on April 10, 2007 at the
Marriott Marquis Hotel in New York
City. Stephen Frantz, PhD, DABT,
MPI Research Director of Pharmaceutical
Development and Senior Principal
Study Director, will be one of three
panelists discussing “FDA Requirements
for New Drug Development – Enabling
Your IND.”
- MPI
Research Expands Toxicology Capacity
New facilities provide timely study
starts to meet the pharmaceutical
industry's growing research and development
needs
- MPI
Research announced the availability of
additional toxicology capacity today. Through its portfolio of services the company
generates critical safety data for the pharmaceutical and biotechnology industries
prior to a new drug candidate's introduction
to humans.
- MPI Research
exhibits (booths 985 and 1546) and
educates at the AAPS Annual Meeting
and Exposition, October 29-November2,
2006 - With
its recent acquisition of Exygen Research,
MPI Research, a leader worldwide in
preclinical drug discovery and development
research, will have an expanded presence
at the Annual Meeting and Exposition
of the American Association of Pharmaceutical
Scientists. Being held October 29 – November
2, 2006 in San Antonio, Texas, meeting
attendees can visit MPI Research in
booths 985 and booth 1546. Booth 985
will focus on the entire scope of services
that are available at MPI Research,
which supports research programs from
drug discovery through regulatory submission.
At booth 1546, our newly enhanced range
of analytical services, which includes
160 talented professionals dedicated
solely to analytical research, 60,000
ft2 of analytical laboratory space,
and 38 LC-MS/MS systems, will be featured.
- MPI Research
Acquires Exygen Research -MPI
Research is pleased to announce its
acquisition of Exygen Research, a Pennsylvania
firm that provides high quality analytical
services to the pharma, biotech, and
chemical industries. Exygen Research
will continue to operate from its State
College PA location and will assume
the management of all analytical services,
including those offered at the Mattawan
site. In addition to substantially
enlarging the analytical scientific
team, laboratory space is also significantly
expanded with this acquisition. Sponsors
will have access to a broader range
of analytical equipment, instrumentation,
and software. Customers currently doing
business with Exygen will now have
access to a greater scope of preclinical
drug discovery and development research
services.
- 2006-09-12 -
MPI Research presents and exhibits
(booth 4) at the 6th Annual Meeting
of the Safety Pharmacology Society,
September 26-28, 2006 in San Diego,
California - MPI Research,
a leader worldwide in preclinical drug
discovery and development research,
is honored to play an active role in
the 6th annual meeting of the Safety
Pharmacology Society, being held September
26-28, 2006 at the Town and Country
Resort and Convention Center in San
Diego, California. We are pleased to
announce a timely program of poster
presentations, detailing the recent
efforts of MPI Research scientists
on our Safety Pharmacology team...
- 2006-07-31
- Join MPI Research
in Booth 323 at the 11th Annual World Congress
on Drug Discovery Technology & Development,
August 8-10 in Boston, MA. - As an industry leader in targeted discovery research, MPI Research is proud to be a part of the 11th Annual World Congress on Drug Discovery Technology and Development. Visit us at BOOTH
323 to learn how the range of models developed by our diverse and experienced drug discovery research team have expedited the discovery and development processes for many of our pharmaceutical, biotech, medical device, and animal health Sponsors. With experience in conducting studies with human as well as rat stem cells, our Sponsors also benefit from the in vitro support available in our tissue culture facility, BSL-2 laboratory for pathogen handling, and our flow cytometry laboratory..
- 2006-07-12
- MPI Research providing GLP training
at the China Life Sciences Summit,
July 27th & 28th in Beijing - As
a global leader in preclinical pharmaceutical,
biopharmaceutical and medical device
research and development, MPI Research
will conduct training on Good Laboratory
Practices (GLP) compliance at the esteemed
China Life Sciences Summit, being held
in Beijing, PRC on July 27-28, 2006.
- 2006-05-24
- Presenting Advances in Therapeutic
Discovery & Drug Development: Molecular
Imaging in Translational Research - Don't
miss out on the exciting developments
that are occurring with non-invasive
molecular imaging in pharmaceutical
research at the upcoming summit, Advances
in Therapeutic Discovery and Drug Development:
Molecular Imaging in Translational
Research. Sponsored by MPI Research,
in collaboration with the Society of
Non-Invasive Imaging in Drug Development
and the Academy of Molecular Imaging,
this summit will be held in the heart
of the life sciences corridor of southwest
Michigan at historic Brook Lodge, the
original estate of The Upjohn Company
founder.
- 2006-05-15
- MPI Research Invites You to Attend
the 2nd Annual Optimizing Preclinical
Outsourcing Conference - MPI
Research would like to invite you to
attend IIR's Second Annual Optimizing
Preclinical Outsourcing Conference
to be held in Cambridge, MA, June 26-28,
2006. Meeting attendees include such
companies as Pfizer Global R&D,
Allergan, Eli Lilly, and Chiron Corp.
It promises to be a spectacular event.
MPI Research is a proud sponsor of
this conference.
- 2006-02-09 -
Join MPI Research in Booth 501 at
the 45th annual Society of Toxicology
meeting March 5-9 in San Diego to
celebrate our decade of excellence! -
MPI Research in commemorationg its
10th year of bringing safer, healthier
pharmaceutical and biotech products
to the world, and would be honored
to have you share in our celebration!
- 2006-01-06 -
MPI Research Board of Directors Approves
$50 Million for 2006 Expansion! ! - In
2005 MPI Research invested $25 million
in our facility, creating 100,000
ft2 of added laboratory space. In
response to further increased demand
for MPI Research services, the Board
of Directors recently approved another
$50 million for 300,000 ft2 of new
construction to come online in 2006.
- 2005-09-14 - ICH
Recommends S7B QT Prolongation Guidelines
for Implementation. MPI CardIon Laboratories
Stand Ready to Assist with Key Preclinical
Assays! - In
May of 2005 the International Conference
on Harmonization (ICH) recommended
for full adoption and implementation
the long discussed and debated S7B
guidelines for the preclinical evaluation
of the potential for delayed ventricular
repolarization (QT interval prolongation)
by human pharmaceuticals.
- 2005-05-24 - MPI
Research Expands Expertise and Support
for Medical Device Research! - In
a continuous effort to improve research
support for the medical device industry,
MPI Research is proud to announce several
major advances to our surgical program.
- 2005-03-03 - MPI
Research Announces the Realignment of
Analytical and DMPK Services into its
MPI Analytical Division at the Annual
Society of Toxicology Meeting in New
Orleans, LA! - MPI
Research announced today the restructuring
of its analytical, ADME and pharmacokinetic
services under one umbrella, MPI Analytical.
In an effort to more closely align related
services, senior management made the
decision to place DMPK and analytical
services into one integrated cohesive
management structure.
- 2005-02-22 - MPI
Research Invites You to Attend Three
Important Breakfast Seminars at the 44th
Annual Meeting of the Society of Toxicology,
March 7th, 8th, and 9th in New Orleans,
LA! - MPI
Research is proud to participate in the
44th annual meeting of the Society of
Toxicology March 6-10, 2005 in New Orleans,
LA. In recognition of the opportunity
for continuing education that the SOT
provides its members, we are pleased
to provide three stimulating breakfast
discussions during this year’s
meeting. MPI Research is honored to have
three leading experts in their fields
offer valuable insight and expertise
on topics that are critical issues in
today’s efforts to bring safe and
effective therapeutics and medical devices
to the marketplace.
- 2005-01-21 - MPI
Research Continues To Set New Standards
for Reporting Preclinical Studies! - MPI
Research has always set itself apart
from other preclinical laboratories by
offering sponsors fast starting, high
quality, preclinical research at competitive
prices.
- 2004-11-03 - MPI
Research Invites 2004 American College
of Toxicology Attendees to Hear Dr. Ted
Baird Discuss the Use of Mini-Swine for
Evaluation of Cardiovascular Safety of
New Drugs - MPI
Research is pleased to announce that
Theodore Baird, Ph.D. will be speaking
at the upcoming American College Of Toxicology
meeting in Palm Springs, California.
As a part of the Safety Pharmacology
symposium on...
- 2004-10-29 - MPI
Research Becomes First US Preclinical
CRO to Add PET Molecular Imaging Services - MPI
Research is proud to announce the availability
of Positron Emission Tomography (PET)
services through a collaborative effort
with Luminare Molecular, a new, leading
edge Molecular Imaging Company...
Home | News
|
